MX2023010278A - Metodos para el tratamiento de la enfermedad ocular tiroidea. - Google Patents

Metodos para el tratamiento de la enfermedad ocular tiroidea.

Info

Publication number
MX2023010278A
MX2023010278A MX2023010278A MX2023010278A MX2023010278A MX 2023010278 A MX2023010278 A MX 2023010278A MX 2023010278 A MX2023010278 A MX 2023010278A MX 2023010278 A MX2023010278 A MX 2023010278A MX 2023010278 A MX2023010278 A MX 2023010278A
Authority
MX
Mexico
Prior art keywords
methods
eye disease
treatment
thyroid eye
thyroid
Prior art date
Application number
MX2023010278A
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey W Sherman
Original Assignee
Horizon Therapeutics Ireland Dac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Ireland Dac filed Critical Horizon Therapeutics Ireland Dac
Publication of MX2023010278A publication Critical patent/MX2023010278A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2023010278A 2021-03-03 2022-03-03 Metodos para el tratamiento de la enfermedad ocular tiroidea. MX2023010278A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163156320P 2021-03-03 2021-03-03
PCT/US2022/018737 WO2022187510A1 (en) 2021-03-03 2022-03-03 Methods for the treatment of thyroid eye disease

Publications (1)

Publication Number Publication Date
MX2023010278A true MX2023010278A (es) 2023-11-21

Family

ID=83154512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010278A MX2023010278A (es) 2021-03-03 2022-03-03 Metodos para el tratamiento de la enfermedad ocular tiroidea.

Country Status (12)

Country Link
US (1) US20240158516A1 (https=)
EP (1) EP4301410A4 (https=)
JP (1) JP2024510142A (https=)
CN (1) CN117813114A (https=)
AR (1) AR125589A1 (https=)
AU (1) AU2022230416A1 (https=)
BR (1) BR112023017797A2 (https=)
CA (1) CA3210855A1 (https=)
CO (1) CO2023012639A2 (https=)
MX (1) MX2023010278A (https=)
TW (1) TW202246339A (https=)
WO (1) WO2022187510A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
US20230406942A1 (en) * 2022-06-10 2023-12-21 Horizon Therapeutics Ireland Dac Igf1r antibodies
WO2024069236A1 (en) * 2022-09-30 2024-04-04 Horizon Therapeutics Ireland Dac Methods for treating inactive or chronic thyroid eye disease
AU2024287547A1 (en) * 2023-07-07 2026-01-22 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
WO2026055673A1 (en) * 2024-09-09 2026-03-12 Viridian Therapeutics, Inc. Methods for treatment of thyroid eye disease with an anti-igf-1r antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3146469B2 (ja) * 1993-09-03 2001-03-19 株式会社ニッショー 自動注射器
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
MX2013008833A (es) * 2011-02-02 2013-12-06 Amgen Inc Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
MX364861B (es) * 2013-04-29 2019-05-09 Hoffmann La Roche Anticuerpos anti-receptor del factor de crecimiento de tipo insulinico humano 1 (anti-igf-1r) con abolicion de la union al fcrn y su uso en el tratamiento de enfermedades oculares vasculares.
HRP20260151T1 (hr) * 2016-08-02 2026-03-27 Visterra, Inc. Modificirani polipeptidi i njihova uporaba

Also Published As

Publication number Publication date
BR112023017797A2 (pt) 2023-11-21
WO2022187510A1 (en) 2022-09-09
EP4301410A4 (en) 2025-03-26
CN117813114A (zh) 2024-04-02
TW202246339A (zh) 2022-12-01
CA3210855A1 (en) 2022-09-09
EP4301410A1 (en) 2024-01-10
CO2023012639A2 (es) 2023-10-09
AU2022230416A1 (en) 2023-09-28
AU2022230416A9 (en) 2024-01-25
AR125589A1 (es) 2023-08-02
US20240158516A1 (en) 2024-05-16
JP2024510142A (ja) 2024-03-06

Similar Documents

Publication Publication Date Title
MX2023010278A (es) Metodos para el tratamiento de la enfermedad ocular tiroidea.
CO2022017670A2 (es) Anticuerpos contra sars-cov-2
BR112022003663A2 (pt) Método para tratar oftalmopatia tireoidiana (ted) em um indivíduo com ted; método para reduzir proptose em pelo menos 2 mm em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de diplopia em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de oftalmopatia tireoidiana (ted); método para reduzir proptose em um olho em um indivíduo com oftalmopatia tireoidiana (ted); método para reduzir pontuação de atividade clínica (cas) de oftalmopatia tireoidiana (ted); método para a) reduzir proptose em pelo menos 2 mm e b) reduzir a pontuação de atividade clínica (cas) em um indivíduo com oftalmopatia tireoidiana (ted); e método para melhorar a qualidade de vida em um indivíduo com oftalmopatia tireoidiana (ted)
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
UA116614C2 (uk) Антитіло до фактора d і його застосування
CL2023001052A1 (es) Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
AR090585A1 (es) Anticuerpos anti-hla-b*27 y usos de estos
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2024008530A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea.
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2023011788A (es) Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos.
CA3242661A1 (en) Compositions and methods for treatment of thyroid eye disease
CO2021014768A2 (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
MX2025009913A (es) Anticuerpos anti-cd3 y metodos para su uso
DOP2024000180A (es) Agentes de interferencia de arn de sarm1
EA201992626A1 (ru) Способы и композиции для лечения аллергических заболеваний глаз
DOP2024000117A (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
BR112022015977A2 (pt) Anticorpos anti-axl e composições
CL2025000591A1 (es) Métodos de tratamiento de la enfermedad de graves mediante anticuerpos anti-fcrn
CR20220122A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
ECSP22004680A (es) Anticuerpos anti-angpt2
BR112022001627A2 (pt) Composições farmacêuticas, minicomprimido, embalagem do tipo stickpack, kit, processo para produzir a composição farmacêutica, métodos para o tratamento de doenças e para tratar tipos específicos de câncer, método de tratamento de câncer em um paciente em necessidade do mesmo e invenção
AR133129A1 (es) Anticuerpos monoclonales humanos neutralizantes contra p. aeruginosa
CL2025002685A1 (es) Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso.